Translational Neuroimmunology In Multiple Sclerosis: From Disease Mechanisms To Clinical…

Hardcover | August 10, 2016

byRuth ArnonEditorAriel Miller, Ruth Arnon

not yet rated|write a review
Multiple sclerosis MS is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS does not currently exist, therapies can help treat MS attacks, attenuate disease activity, reduce progress of the disease, and manage symptoms. Translational Neuroimmunology in Multiple Sclerosis provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis, from experimental models and the human disease to the translation of this research to immunotherapeutic strategies. Chapters describe genetic and environmental factors underlying the disease pathogenesis of MS as a basis for development of immunotherapies, immunological markers of disease activity, pharmacogenetics, and responses to therapy. Immunomodulatory therapies currently in practice and future therapeutic strategies on the horizon such as neuroprotective strategies, stem cells, and repair promotion are discussed. Contributed by renowned leaders in the field, this cross-disciplinary volume is a great resource for basic scientists and clinical practitioners in neuroscience, neurology, immunology, pharmacology, and in-drug development. Provides an overview of recent findings and knowledge of the neuroimmunology of multiple sclerosis and the translation of this research to immunotherapy treatment Edited by renowned leaders in the field of neuroimmunology and multiple sclerosis Contains the latest resource material for basic and clinical scientists and practitioners in neuroscience, neurology, immunology, and pharmacology

Pricing and Purchase Info

$144.04 online
$172.50 list price (save 16%)
In stock online
Ships free on orders over $25

From the Publisher

Multiple sclerosis MS is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS doe...

From the Jacket

Multiple sclerosis (MS) is the most common disabling neurological disease of young adults. More than 2.3 million people are affected by MS worldwide. Symptoms can vary widely, depending on the localization and amount of the damage induced by combined inflammatory, demyelinating, and neurodegenerative processes. Although a cure for MS d...

PROF. RUTH ARNON, formerly Vice-President of the Weizmann Institute of Science (1988-1997), is a renowned immunologist. Prof. Arnon joined the Institute in 1960. Prior to her appointment as Vice-President, she served as Head of the Department of Chemical Immunology, and as Dean of the Faculty of Biology. From 1985 to 1994, she was the ...

other books by Ruth Arnon

Eradicating Child Maltreatment: Evidence-Based Approaches to Prevention and Intervention Across…
Eradicating Child Maltreatment: Evidence-Based Approach...

Kobo ebook|Sep 28 2014

$33.19 online$43.07list price(save 22%)
Format:HardcoverDimensions:502 pages, 9.41 × 7.24 × 0.98 inPublished:August 10, 2016Publisher:Academic PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:012801914X

ISBN - 13:9780128019146

Look for similar items by category:

Customer Reviews of Translational Neuroimmunology In Multiple Sclerosis: From Disease Mechanisms To Clinical Applications

Reviews

Extra Content

Table of Contents

Section I: MS Pathology and Mechanisms 1. MS Pathology: Inflammation versus Neurodegeneration 2. Immune Dysregulation in Multiple Sclerosis 3. CNS immune regulation 4. Genetics of Multiple Sclerosis 5. MS Subtypes: How the Natural History of MS was Challenged Due to Treatment 6. Pediatric-Onset MS as a Window into Early Disease Targets and Mechanisms 7. Sex-related factors in multiple sclerosis

Section II: Other Patho-Mechanisms 8. Environmental Factors and their regulation of immunity in MS 9. Gut Microbiota in Multiple Sclerosis: A Bioreactor driving Brain Autoimmunity 10. Neuroendocrine Checkpoints of Innate Immune Responses in Multiple Sclerosis: Reciprocal Interactions Between Body and Brain 11. Fighting chronic neuroinflammation by boosting autoimmunity: the distinction between neurodegenerative diseases and multiple sclerosis 12. Neuroactive steroids and Neuroinflammation

Section III: Surrogate Markers in Multiple Sclerosis 13. Surrogate Markers in Multiple Sclerosis: The Role of MRI

Section IV: Currently Approved Therapies Injectable 14. Interferon ß in Multiple Sclerosis: A Review 15. Glatiramer Acetate - From Bench to Bed and Back 16. Natalizumab 17. Alemtuzumab (Campath-1H) 18. Currently approved DMDs-injectable: cytotoxic immunosuppressive drugs

Section V: Currently Approved DMDs Oral 19. Fingolimod (Gilenya) 20. Oral Dimethyl Fumarate (BG-12; Tecfidera®) for Multiple Sclerosis 21. Emerging Therapies for Multiple Sclerosis

Section VI: Symptomatic and Complementary Treatments 22. Treatment of acute relapses in Multiple sclerosis 23. Shedding light on Vitamin D and MS 24. Symptomatic and Complementary Treatments 25. Cognitive Impairment in Multiple Sclerosis

Section VII: Novel and Emerging Strategies 26. Personalized Medicine and Theranostics: Applications to Multiple Sclerosis 27. Stem cell based-therapies, remyelination and repair promotion, in the treatment of multiple sclerosis 28. Stem cells in Multiple Sclerosis 29. T cell vaccination: An insight into T cell regulation 30. Reversal of Misfortune: Therapeutic Strategies on the Horizon